FGF2 and neoplasm: Consistently, de Langen et al. demonstrated that patients with a significant decrease in SUV or tumor perfusion three weeks post bevacizumab and erlotinib treatment had longer survival [12], and Kelly et al. demonstrated correlations between changes in kep and serum basic fibroblast growth factor and progression-free survival in patients who received sorafenib [13].